Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the
Read Article
No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.
Read Article
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read Article
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Data derived from the retrospective
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Read Article
Links:
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).
Read Article
Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.
Read Article
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
